Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers.

Hiroyuki TakedaKiyomi ImotoKumiko UmemotoAyako DoiHiroyuki AraiYoshiki HorieTakuro MizukamiTomoyo OguriTakashi OguraNaoki IzawaHiroyuki YamamotoYoshihisa YamanoYu Sunakawa

Published in: Targeted oncology (2022)

Although their genomic profiles revealed fewer druggable sites, patients with GI cancers accessed targeted therapies similarly to patients with non-GI cancers. The utility of genomic profile testing in patients with GI cancers was highlighted to determine if patients can receive specific treatments, such as HER2-targeted and BRAF-targeted therapies.

Keyphrases

end stage renal disease
copy number
ejection fraction
newly diagnosed
chronic kidney disease
single cell
peritoneal dialysis
young adults
patient reported outcomes
cancer therapy
dna methylation
drug delivery
patient reported
wild type